GC Corp. Increases Stake in Artiva Biotherapeutics to 12.3% via Underwritten Offering

On May 28, 2026, GC Corp. and its affiliates filed a Schedule 13D/A regarding their holdings in Artiva Biotherapeutics, Inc. (ARTV). The reporting group, which includes GC Corp., GC Cell Corporation, and Yong-Jun Huh, increased their collective position through participation in an underwritten offering on May 11, 2026. Specifically, GC Corp purchased 1,085,069 shares and GC Cell Corporation purchased 347,222 shares, both at a price of $11.52 per share. Following these transactions, the reporting group beneficially owns a total of 5,999,703 shares of Common Stock, representing 12.3% of the outstanding shares. GC Corp. directly holds 4,391,969 shares, while GC Cell Corporation directly holds 1,607,734 shares. Yong-Jun Huh, as CEO of GC Corp., may be deemed to share beneficial ownership of all reported shares. The acquisition was funded using approximately $16.5 million of GC Corp.'s working capital. This filing serves as Amendment No. 1 to the original Schedule 13D filed in July 2024.